Vygoris is a new company in the UK.
We develop sophisticated niche generic pharmaceuticals.
We pride ourselves in being innovative, proactive and experts in the development of complex and difficult to manufacture formulations.
We strive for excellence in all that we do and we aim to offer our clients around the globe high quality pharmaceutical products and comprehensive service.
A young, dynamic and vibrant company, we’re driven by an ambition to deliver results. Our team is continually seeking the next opportunity, through forthcoming patent expirations or new ventures. We look for pharmaceutical products with a degree of complexity, technological difficulty and clinical and manufacturing risk, choosing to work in niche pharmaceutical markets where we can make a truly positive difference to our customers.
Your Content Goes Here
Your Content Goes Here
About Us
Vygoris Ltd is a subsidiary of Substipharm, a privately owned French specialist generics company.
We are launching shortly in the UK with a recently acquired urology product, Mitocin, for use primarily in bladder cancer.
Our aim is to introduce innovative and difficult to manufacture specialist products, in a range of therapy areas.
Products
Vygoris’ first launch in the UK is in bladder cancer. Further information will shortly be available on the Mitocin website.
